Free Trial

Brokers Issue Forecasts for EWTX Q2 Earnings

Edgewise Therapeutics logo with Medical background

Edgewise Therapeutics, Inc. (NASDAQ:EWTX - Free Report) - Investment analysts at HC Wainwright issued their Q2 2025 earnings per share estimates for Edgewise Therapeutics in a report issued on Monday, June 30th. HC Wainwright analyst J. Pantginis forecasts that the company will earn ($0.41) per share for the quarter. HC Wainwright currently has a "Buy" rating and a $42.00 target price on the stock. The consensus estimate for Edgewise Therapeutics' current full-year earnings is ($1.45) per share. HC Wainwright also issued estimates for Edgewise Therapeutics' Q3 2025 earnings at ($0.45) EPS, Q4 2025 earnings at ($0.46) EPS, FY2025 earnings at ($1.75) EPS, FY2026 earnings at ($2.12) EPS, FY2027 earnings at ($1.93) EPS, FY2028 earnings at ($0.97) EPS and FY2029 earnings at $3.10 EPS.

Edgewise Therapeutics (NASDAQ:EWTX - Get Free Report) last announced its earnings results on Thursday, May 8th. The company reported ($0.43) EPS for the quarter, topping the consensus estimate of ($0.45) by $0.02.

Several other equities analysts have also recently issued reports on EWTX. Guggenheim started coverage on Edgewise Therapeutics in a report on Wednesday, April 30th. They issued a "buy" rating and a $41.00 price target on the stock. Wedbush reiterated an "outperform" rating and set a $43.00 price objective on shares of Edgewise Therapeutics in a report on Monday, April 21st. Piper Sandler reiterated an "overweight" rating and set a $51.00 price objective on shares of Edgewise Therapeutics in a report on Wednesday, April 2nd. Scotiabank cut Edgewise Therapeutics from a "sector outperform" rating to a "sector perform" rating and cut their target price for the company from $50.00 to $14.00 in a research note on Wednesday, April 2nd. Finally, Royal Bank Of Canada reaffirmed an "outperform" rating and set a $48.00 price target on shares of Edgewise Therapeutics in a research report on Thursday, June 5th. Two research analysts have rated the stock with a hold rating and eight have assigned a buy rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and a consensus price target of $40.00.

View Our Latest Stock Analysis on Edgewise Therapeutics

Edgewise Therapeutics Trading Down 0.4%

Edgewise Therapeutics stock traded down $0.06 during mid-day trading on Wednesday, hitting $12.96. The stock had a trading volume of 361,183 shares, compared to its average volume of 1,194,176. The stock has a 50-day simple moving average of $14.62 and a two-hundred day simple moving average of $20.50. The stock has a market capitalization of $1.36 billion, a PE ratio of -8.36 and a beta of 0.25. Edgewise Therapeutics has a 12 month low of $10.60 and a 12 month high of $38.12.

Insider Buying and Selling

In other Edgewise Therapeutics news, insider Alan J. Russell sold 1,551 shares of the business's stock in a transaction on Friday, May 2nd. The stock was sold at an average price of $16.45, for a total value of $25,513.95. Following the sale, the insider directly owned 18,521 shares in the company, valued at $304,670.45. The trade was a 7.73% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, CEO Kevin Koch sold 4,276 shares of the business's stock in a transaction dated Friday, May 2nd. The stock was sold at an average price of $16.45, for a total value of $70,340.20. Following the transaction, the chief executive officer owned 20,619 shares of the company's stock, valued at approximately $339,182.55. The trade was a 17.18% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 14,258 shares of company stock worth $234,544 in the last ninety days. Corporate insiders own 23.20% of the company's stock.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently made changes to their positions in the company. Summit Investment Advisors Inc. lifted its holdings in shares of Edgewise Therapeutics by 6.8% during the 4th quarter. Summit Investment Advisors Inc. now owns 7,594 shares of the company's stock valued at $203,000 after buying an additional 482 shares during the period. Caitong International Asset Management Co. Ltd grew its position in Edgewise Therapeutics by 55.6% in the first quarter. Caitong International Asset Management Co. Ltd now owns 3,194 shares of the company's stock worth $70,000 after acquiring an additional 1,141 shares in the last quarter. Alliancebernstein L.P. lifted its stake in Edgewise Therapeutics by 1.7% in the fourth quarter. Alliancebernstein L.P. now owns 77,260 shares of the company's stock worth $2,063,000 after purchasing an additional 1,300 shares during the last quarter. Arizona State Retirement System raised its stake in shares of Edgewise Therapeutics by 12.3% during the first quarter. Arizona State Retirement System now owns 12,201 shares of the company's stock valued at $268,000 after acquiring an additional 1,338 shares in the last quarter. Finally, Diadema Partners LP bought a new position in Edgewise Therapeutics in the fourth quarter worth approximately $36,000.

Edgewise Therapeutics Company Profile

(Get Free Report)

Edgewise Therapeutics, Inc, a biopharmaceutical company, discovers, develops, and commercializes therapies for the treatment of muscle disorders. Its lead product candidate, EDG-5506, an orally administered small molecule that is in Phase II clinical trials, designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy and Becker muscular dystrophy.

Featured Articles

Earnings History and Estimates for Edgewise Therapeutics (NASDAQ:EWTX)

Should You Invest $1,000 in Edgewise Therapeutics Right Now?

Before you consider Edgewise Therapeutics, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Edgewise Therapeutics wasn't on the list.

While Edgewise Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

Options Trading Made Easy - Download Now Cover

Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

3 “Boring” Mega Cap Stocks to Turn Into Pure Profit
Joby vs. Archer: The $10 Billion eVTOL Battle
3 Small-Cap Biotech Stocks With Catalysts Too Big to Ignore

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines